Patents by Inventor Mark A. Kester
Mark A. Kester has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180064347Abstract: Systems comprising a combination of the handheld imaging system with a nanoparticle multimodal contrast agent are disclosed. The imaging system exploits the advantages of both near-infrared emission and the photoacoustic effect by employing calcium phosphosilicate nanocolloid that encapsulates NIR and CT/MRI contrast agents for enhanced deep tissue imaging as well as a portable NIR/PA system using a tunable pulsed laser, CCD imaging technology and acoustic transducer arrays. Methods for using the system, for example in rapid diagnosis of trauma such as that inflicted on a battlefield, are provided.Type: ApplicationFiled: September 8, 2017Publication date: March 8, 2018Inventors: JAMES H. ADAIR, SEAN D. KNECHT, J. ERIC BOYER, RICHARD L. TUTWILER, CONNOR CARR, XIAOMENG TANG, BERNADETTE M. ADAIR, THOMAS NEUBERGER, WELLEY S. LOC, ZACHARY R. WILCZYNSKI, CHRISTOPHER MCGOVERN, GAIL L. MATTERS, KEITH CHENG, MARK KESTER, LAWRENCE SINOWAY
-
Publication number: 20170274100Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: ApplicationFiled: October 2, 2015Publication date: September 28, 2017Inventors: James H. Adair, Erhan Altinoglu, Brian M. Barth, James M. Kaiser, Mark Kester, Gail L. Matters, Christopher McGovern, Thomas T. Morgan, Sriram S. Shanmugavelandy, Rahul Sharma, Jill P. Smith
-
ENCAPSULATION AND HIGH LOADING EFFICIENCY OF PHOSPHORYLATED DRUG AND IMAGING AGENTS IN NANOPARTICLES
Publication number: 20170209478Abstract: Method of producing nanoparticle of drug and imaging agents are provided. The phosphorylated encapsulated drugs and imaging agents could be encapsulated at therapeutic levels, were encapsulated at higher amounts. The CPSNPs were more effective in treating cancer, in reducing cancer proliferation, arresting cancer cell growth than when not in the form of a CPSNP, and showed efficacious treatment of cancer cells at far lower dosage than free molecules. Calcium phosphosilicate and phosphate nanoparticles are disclosed and their method of use. The methods and nanoparticles are particularly efficacious where CPSNPs were used to encapsulate 5-FU metabolites such as FdUMP and gemcitabine metabolites.Type: ApplicationFiled: January 20, 2017Publication date: July 27, 2017Inventors: James H. Adair, Gail Matters, Welley S. Loc, Amra Tabakovic, Mark Kester, Sam Linton, Christopher McGovern, Christopher Gigliotti, Xiaomeng Tang, Peter J. Butler, Gary A. Clawson, Jill P. Smith -
Publication number: 20160206633Abstract: Use of dhS1P and/or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and/or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patient's immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.Type: ApplicationFiled: January 15, 2016Publication date: July 21, 2016Inventors: Brian M. Barth, Mark Kester, James H. Adair, Todd E. Fox
-
Patent number: 9326953Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: GrantFiled: November 9, 2012Date of Patent: May 3, 2016Assignee: The Penn State Research FoundationInventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Patent number: 9149544Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: GrantFiled: November 8, 2010Date of Patent: October 6, 2015Assignee: THE PENN STATE RESEARCH FOUNDATIONInventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern
-
Publication number: 20150165053Abstract: Stable, non-toxic, calcium phosphate nanoparticles are formed that incorporate one or more oligonucleotides. RNAi nucleotides may be incorporated and, in particular, siRNA nucleotides. Since the siRNA nanoparticles dissociate leaving only naturally occurring residual materials, calcium and phosphate, along with the siRNA, they are particularly useful as carrier vehicles. The ability to incorporate more than one siRNA provides a means to block or knock down the translation of multiple targeted proteins at the same time.Type: ApplicationFiled: August 10, 2013Publication date: June 18, 2015Inventors: Mylisa Parette, Danielle Asquino, Kari Eyer, James Adair, Jeffrey Davidson, Mark Kester
-
Patent number: 9028863Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: GrantFiled: April 26, 2004Date of Patent: May 12, 2015Assignee: The Penn State Research FoundationInventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Publication number: 20140348901Abstract: The invention relates to combining targeted therapies with selected chemotherapeutics for the treatment of melanoma. The invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity, a method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces Akt3 activity to restore normal apoptotic sensitivity to a melanoma tumor cell, allowing a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient. Also disclosed is a method for treating a melanoma comprising administering an agent that reduces Akt3 activity and an agent that reduces V599E B-Raf activity, thereby treating a melanoma tumor.Type: ApplicationFiled: April 25, 2014Publication date: November 27, 2014Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Gavin P. Robertson, Lakshman Segar, Mark Kester, Arati K. Sharma
-
Patent number: 8889640Abstract: Gastrin mRNA down-regulation using either stable transfection of an antisense gastrin cDNA or one of three shRNA (short hairpin RNA) constructs achieves significant reduction in growth of human pancreatic cancer. Tumor growth rate and incidence of metastases in both wild type and transfected pancreatic cancer cells is directly proportional to the degrees of gastrin mRNA expression. In order to avoid rapid degradation of injected siRNA, nanoliposomes can be loaded with gastrin siRNA and used to deliver the siRNA to the tumors. Significant reduction of tumors in mice using siRNA loaded nanoliposomes is achieved. Uptake of pegylated nanoliposomes by tumor cells depends upon the pegylation percentage.Type: GrantFiled: June 22, 2009Date of Patent: November 18, 2014Inventors: Jill P. Smith, Mark Kester, Gail L. Matters, John F. Harms
-
Publication number: 20140271824Abstract: The present invention relates to a liposomal formulation for oral delivery of a bioactive agent that considers pH stability and oxidative stability of a bioactive ingredient. These lipid formulations are superior to conventional liposomes due to their stability, thereby circumventing the need for intra-venous delivery of bioactive agents. In one embodiment, the methods and compositions of the present invention relate to the oral delivery of insulin or a prodrug thereof.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: The Penn State Research FoundationInventors: Mark Kester, Karam El-Bayoumy, Christine Skibinski, Arunangshu Das
-
Publication number: 20140212480Abstract: Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes.Type: ApplicationFiled: April 3, 2014Publication date: July 31, 2014Applicant: The Penn State Research FoundationInventors: Mark Kester, Sriram S. Shanmugavelandy, Todd Fox
-
Publication number: 20140205669Abstract: Use of dhS1P and/or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and/or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patient's immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.Type: ApplicationFiled: November 26, 2013Publication date: July 24, 2014Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Brian M. Barth, Mark Kester, James H. Adair, Todd E. Fox
-
Patent number: 8771741Abstract: Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.Type: GrantFiled: January 22, 2010Date of Patent: July 8, 2014Assignee: The Penn State Research FoundationInventors: James H. Adair, Mark Kester, Erhan I. Altinoglu, Brian M. Barth, Timothy J. Russin, James M. D. Kaiser, Thomas T. Morgan, Karen L. Eklund
-
Patent number: 8747891Abstract: Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes.Type: GrantFiled: May 10, 2012Date of Patent: June 10, 2014Assignee: The Penn State Research FoundationInventors: Mark Kester, Sriram S. Shanmugavelandy, Todd Fox
-
Publication number: 20140154325Abstract: Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: James H. Adair, Mark Kester, Peter C. Eklund, Erhan I. Altinoglu, Brian M. Barth, Timothy J. Russin, James M.D. Kaiser, Thomas T. Morgan
-
Publication number: 20130295159Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: ApplicationFiled: November 9, 2012Publication date: November 7, 2013Inventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Publication number: 20120288556Abstract: Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes.Type: ApplicationFiled: May 10, 2012Publication date: November 15, 2012Applicant: The Penn State Research FoundationInventors: Mark Kester, Sriram S. Shanmugavelandy, Todd Fox
-
Patent number: 8071132Abstract: The present invention provides a method for the synthesis of unagglomerated, highly dispersed, stable core/shell nanocomposite particles comprised of preparing a reverse micelle microemulsion that contains nanocomposite particles, treating the microemulsion with a silane coupling agent, breaking the microemulsion to form a suspension of the nanocomposite particles by adding an acid/alcohol solution to the microemulsion that maintains the suspension of nanocomposite particles at a pH of between about 6 and 7, and simultaneously washing and dispersing the suspension of nanocomposite particles, preferably with a size exclusion HPLC system modified to ensure unagglomeration of the nanocomposite particles. The primary particle size of the nanocomposite particles can range in diameter from between about 1 to 100 nm, preferably from between about 10 to 50 nm, more preferably about 10 to 20 nm, and most preferably about 20 nm.Type: GrantFiled: June 1, 2005Date of Patent: December 6, 2011Assignee: The Penn State Research FoundationInventors: James H. Adair, Sarah M. Rouse, Jun Wang, Mark Kester, Christopher Siedlecki, William B. White, Erwin Vogler, Alan Snyder, Carlo G. Pantano, Victor Ruiz-Velasco, Lawrence Sinoway
-
Publication number: 20110129413Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: ApplicationFiled: November 8, 2010Publication date: June 2, 2011Inventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern